Background {#Sec1}
==========

Multiple epidemiologic studies have demonstrated that advanced age \[[@CR1]\], pulmonary basilar rales \[[@CR2]\], dyspnea \[[@CR3]\], QRS duration \[[@CR4]\] cardiomegaly \[[@CR5]\], higher urea \[[@CR6]\], higher potassium \[[@CR7], [@CR8]\] lower sodium \[[@CR9]\], higher B-type Natriuretic Peptide (BNP) \[[@CR10]\], and lower hemoglobin \[[@CR11]\] at presentation are all associated with in-hospital mortality among patients with acute decompensated heart failure (ADHF). BNP is among the most powerful prognostic markers in all forms of clinical heart failure (HF) \[[@CR12]\]; it is recognized as a gold standard marker for outcome prediction in HF \[[@CR11], [@CR13]--[@CR15]\]. Clinically relevant characteristics of Asian populations and the clinical prognostic factors with hospitalized ADHF have not been fully studied in a large observational cohort. The aims of this study are to explore the clinical characteristics relevant to abnormal BNP among unplanned hospitalized with ADHF and to further evaluate determinants of in-hospital mortality among ADHF in an Asian population.

Methods {#Sec2}
=======

This retrospective study of ADHF used electronic medical records to investigate 1,807 consecutive patients aged 20+ who were hospitalized and discharged with a main clinical diagnosis of HF from March 2013 to March 2014 in an urban tertiary teaching hospital in Taiwan. Datasets were collected as routine medical management and hospitalization claims covered under the National Health Insurance Bureau of Taiwan. Heart failure was defined by using the European Society of Cardiology guidelines \[[@CR16]\]. Hospitalization for heart failure was defined as unplanned presentation at our emergency department of patients receiving intravenous diuretic (e.g. loop diuretics, such as furosemide) or vasodilator treatment of new or worsening HF requiring admission to our hospital \[[@CR17], [@CR18]\]. Definition of ADHF in our current work was made by new onset or rapidly worsening HF signs and symptoms requiring urgent and unplanned hospitalization \[[@CR15], [@CR19], [@CR20]\]. As in previous hospitalized acute HF studies, BNP \>100 pg/ml was used as the cut-off for abnormally high BNP levels \[[@CR21], [@CR22]\]. Initial admission findings were mainly collected in the emergency department. Clinical information including cardiomegaly and data about left ventricular ejection fraction (LVEF) were collected from echocardiography. Pharmaceutical intravenous drugs administered at the emergency department were abstracted. Medical histories of chronic heart failure (CHF), hypertension, diabetes, coronary artery disease (CAD), chronic kidney disease (CKD), dyslipidemia, stroke, and anemia were abstracted as documented in electronic medical records. The main exclusion criteria were end stage renal disease or initial admission creatinine \>3 mg/dl, acute coronary syndrome (including myocardial infarction or unstable angina), dialysis, terminal stage malignancy, liver cirrhosis, or life expectancy less than 6 months.

Statistical analysis {#Sec3}
--------------------

Baseline characteristics of ADHF patients were expressed as mean (standard deviation) for continuous variables and frequency (percentage) for categorical variables. Student T tests were used to test the differences between groups for demographic characteristics and echocardiography-derived measures or indices. Chi-square or the Fisher exact test was used for comparisons of proportional distributions of cardiovascular risk factors between groups, as appropriate. The risk factors of all causes of in-hospital mortality were determined using univariate and multivariate Cox proportional hazard regression models. The cumulative probability of in-hospital mortality by the BNP groups (\>100 or ≤ 100 pg/ml) was graphically presented using the Kaplan Meier survival function with comparison of cumulative events by the log-rank test. The relationship between in-hospital mortality and levels of BNP at admission was presented using locally weighted smoothing regression scatterplots. The trend of in-hospital mortality by quartiles (Q) of BNP were Q1 \< 260.5, Q2 260.5 to 617, Q3 618 to 1340, Q4 1341+ pg/ml was graphically presented using the Kaplan Meier survival function with comparison of cumulative events by chi-square. A two-sided *p* value \< 0.05 was considered as a statistically significant difference. All clinical variables *p* \< 0.10 in univariate Cox model were entered into multivariate analysis. All statistical analyses were performed with Stata statistical software package (StataCorp. 2011. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP.)

Results {#Sec4}
=======

Baseline demographic differences based on BNP level in admitted ADHF individuals {#Sec5}
--------------------------------------------------------------------------------

A total of 1807 patients participated in our cohort study: 927 were female (51.3 %), the mean age was 75.27 ± 14.12 years with ages ranging from 20+ to 103, and average BNP levels were 1028.11 ± 1136.22 pg/ml. The baseline characteristics stratified by BNP group are presented in Table [1](#Tab1){ref-type="table"}. More advanced age (76.3 vs 72.3 years, *p* = 0.003) was observed at admission in patients with abnormally high levels of BNP (BNP \> 100 pg/ml); no gender distribution differences was observed (*p* = 0.63). Initial admission findings show that pulmonary basilar rales, worse NYHA FC, peripheral edema, lower LVEF, higher urine acid, higher urea, higher creatinine, lower glomerular filtration rate (GFR), higher potassium, lower hemoglobin, and a higher prevalence of medical histories of CKD and A-fib were observed in those patients with BNP \>100 pg/ml versus patients with BNP ≤100 pg/ml. Length of hospital stay and admission vital signs, including blood pressure and heart rates, showed no differences between the BNP ≤ 100 and \>100 pg/ml groups. Univariate and multivariate analyses for clinical determinants of in-hospital mortality are presented in Table [2](#Tab2){ref-type="table"}.Table 1Baseline characteristics categorized by BNP groupVariableAll patients\
(*n* = 1807)BNP ≤ 100\
(*n* = 130)BNP \> 100\
(*n* = 1677)*p*-valueAge (year)75.27 (14.12)72.29 (14.53)76.25 (14.07)0.003Gender Female927 (51.30 %)65 (50.0 %)876 (52.23 %)0.630 Male880 (48.69 %)65 (50.0 %)801 (47.77 %)Mortality Alive1569 (86.83 %)122 (93.85 %)1421 (84.76 %)0.005 Death238 (13.17 %)8 (6.15 %)256 (15.24 %)Stay in hospital (day)12.05 (40.71)14.34 (20.79)14.33 (35.6)0.985Initial admission findings Heart rate (beats/min)90.27 (21.60)91.83 (18.77)92.81 (22.91)0.584 SBP (mmHg)135.87 (28.11)135.59 (28.45)136.33 (29.46)0.786 DBP (mmHg)74.26 (17.53)73.26 (17.09)74.41 (18.58)0.501 Rales599 (33.15 %)36 (27.69 %)467 (41.62 %)0.002 PND39 (2.15 %)2 (1.54 %)35 (3.12 %)0.314 Orthopnea138 (7.64 %)7 (5.38 %)122 (10.87 %)0.051 NYHA FC (III-IV)591 (32.70 %)45 (34.62 %)475 (42.34 %)0.091 Peripheral edema473 (26.18 %)30 (23.08 %)357 (31.82 %)0.041 QRS duration (ms)101.91 (24.92)99.73 (23.01)102.94 (25.44)0.141 LVEF (%)54.33 (13.70)60.05 (9.68)52.97 (14.09)\<0.001 Cardiomegaly667 (36.91 %)56(43.08 %)516 (45.99 %)0.528 Glucose (mg/dl)168.35 (93.67)172.16 (101.59)178.56 (96.64)0.480 HbA1c (%)6.75 (1.74)6.64 (1.68)6.80 (1.75)0.649 Total bilirubin (mg/dl)1.31 (2.21)0.93 (0.59)1.38 (2.49)0.072 GPT (u/l)37.50 (70.82)35.98 (63.76)41.52 (80.69)0.268 Urine acid (mg/dl)7.32 (2.79)6.62 (2.25)7.72 (2.83)\<0.001 Urea (mg/dl)28.63 (17.92)24.59 (17.02)30.42 (18.00)\<0.001 Creatinine (mg/dl)1.46 (0.74)1.28 (0.65)1.54 (0.76)\<0.001 GFR (ml/min/1.73 m^2^)54.0 (30.90)62.38 (31.14)50.27 (28.89)\<0.001 Potassium (meq/l)4.08 (0.77)3.89 (0.64)4.09 (0.81)0.001 Sodium (meq/l)136.62 (6.14)136.67 (5.65)136.31 (6.42)0.547 Troponin (ng/ml)0.51 (3.62)0.22 (1.68)0.57 (4.06)0.340 BNP (pg/ml)1028.11 (1136.22)46.81 (27.13)1141.81 (1147.18)\<0.001 Hemoglobin (g/dl)11.40 (2.57)12.29 (2.70)11.25 (2.54)\<0.001Medical history (*n*, %) CHF1050 (58.11 %)62 (47.69 %)988 (54.63 %)0.133 Hypertension1100 (60.87 %)81 (62.31 %)1019 (59.36 %)0.516 Diabetes752 (41.62 %)59 (45.38 %)693 (42.25 %)0.493 CAD435 (24.07 %)27 (20.77 %)408 (22.37 %)0.677 CKD395 (21.86 %)18 (13.85 %)377 (23.89 %)0.010 Dyslipidemia376 (20.81 %)30 (23.08 %)346 (18.72 %)0.232 Stroke300 (16.60 %)30 (23.08 %)270 (17.91 %)0.151 A-fib396 (21.91 %)13 (10.0 %)383 (24.24 %)\<0.001 Anemia167 (9.24 %)9 (6.92 %)158 (9.98 %)0.264 Hepatitis38 (2.10 %)4 (3.08 %)34 (2.23 %)0.543Medications (*n*, %) Diuretics1432 (79.26 %)85 (65.38 %)1347 (80.32 %)\<0.001 Nitrates844 (46.7 %)91 (70.00 %)753 (44.90 %)\<0.001 Digoxin87 (4.86 %)4 (3.08 %)83 (4.95 %)0.337 Beta blocker72 (3.98 %)0 (0 %)72 (4.29 %)0.016*Abbreviations*: *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *PND* paroxysmal nocturnal dyspnea, *NYHA FC* New York Heart Association functional class, *LVEF* left ventricular ejection fraction, *HbA1c* glycated hemoglobin, *GPT* glutamate pyruvate transaminase, *GFR* glomerular filtration rate, *BNP* B-type natriuretic peptide, *CHF* chronic heart failure, *CAD* coronary artery disease, *CKD* chronic kidney disease, A-fib atrial fibrillationTable 2Predictors of in-hospital mortality (univariate and multivariate analysis)UnivariateMultivariateVariablesHR\[95 % C.I. for HR\]*P*-valueHR\[95 % C.I. for HR\]*P*-valueAge (year)1.692(1.152, 2.486)0.0071.020(1.01, 1.03)0.007Gender (Male/Female)1.102(0.849, 1.430)0.464Heart rate (beats/min)1.004(0.999, 1.009)0.152SBP (mmHg)0.997(0.993, 1.001)0.177DBP (mmHg)0.995(0.988, 1.003)0.223Rales1.709(1.317, 2.218)\<0.0011.500(1.065, 2.114)0.02PND0.526(0.131, 2.121)0.367Orthopnea0.645(0.359, 1.160)0.143NYHA FC (III-IV)1.980(1.436, 2.433)\<0.0011.662(1.288, 3.052)0.002Peripheral edema0.824(0.595, 1.141)0.243QRS duration (ms)1.007(1.002, 1.012)0.0071.010(1.001, 1.01)0.023LVEF (%)1.002(0.988, 1.015)0.812Cardiomegaly1.505(1.151, 1.969)0.0030.945(0.617, 1.448)0.796Glucose (mg/dl)0.999(0.998, 1.001)0.359HbA1c (%)0.801(0.627, 1.023)0.076Total bilirubin (mg/dl)1.052(1.009, 1.098)0.0181.037(0.978, 1.099)0.222GPT (u/l)1.000(0.998, 1.001)0.618Urine acid (mg/dl)1.046(0.994, 1.101)0.081Creatinine (mg/dl)1.106(0.939, 1.304)0.227GFR (ml/min/1.73 m^2^)1.000(0.996, 1.005)0.833Potassium (meq/l)1.262(1.109, 1.436)\<0.0011.125(0.939, 1.347)0.202Sodium (meq/l)0.978(0.961, 0.995)0.0101.000(0.973, 1.027)0.979Troponin (ng/ml)1.004(0.963, 1.046)0.864BNP (\>100/≤100)2.486(1.218, 5.071)0.0122.170(1.145, 6.640)0.024Hemoglobin (g/dl)0.904(0.856, 0.954)\<0.0010.971(0.901, 1.046)0.433CHF0.779(0.600, 1.012)0.161Hypertension0.672(0.517, 0.872)0.303Diabetes0.770(0.587, 1.009)0.158CAD0.801(0.558, 1.149)0.228CKD0.565(0.380, 0.839)0.505Dyslipidemia1.321(0.967, 1.806)0.180Stroke0.942(0.673, 1.317)0.726A-fib0.455(0.306, 0.676)0.101Anemia0.655(0.394, 1.089)0.103Hepatitis1.351(0.666, 2.739)0.404*Abbreviations*: *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *PND* paroxysmal nocturnal dyspnea, *NYHA FC* New York Heart Association functional class, *LVEF* left ventricular ejection fraction, *HbA1c* glycated hemoglobin, *GPT* glutamate pyruvate transaminase, *GFR* glomerular filtration rate, *BNP* B-type natriuretic peptide, *CHF* chronic heart failure, *CAD* coronary artery disease, *CKD* chronic kidney disease, A-fib atrial fibrillation

Clinical predictors for in-hospital mortality {#Sec6}
---------------------------------------------

In a univariate Cox model, advanced age, presentation at admission with pulmonary basilar rales, worse NYHA FC, cardiomegaly, wider QRSD, higher total bilirubin, higher potassium, lower sodium, abnormally high BNP and lower hemoglobin were all associated with in-hospital mortality among ADHF patients (all *p* \< 0.05). Multivariate Cox proportional hazard regression analysis was further performed to determine the independent risk factors associated with in-hospital mortality. After adjusting for age, gender, rales, NYHA FC, QRSD, cardiomegaly, total bilirubin, urine acid, urea, potassium, sodium, BNP, and hemoglobin we found that more advanced age (HR: 1.02, 95 % CI: 1.01--1.03), presence of rales (HR: 1.50, 95 % CI: 1.07--2.11), worse NYHA FC (HR: 1.66, 95 % CI: 1.29--3.05), more widened QRS duration (HR: 1.01, 95 % CI: 1.001--1.01) and admission with abnormally high BNP (\>100 pg/ml, HR: 2.17, 95 % CI: 1.15--6.64) were associated with in-hospital mortality among hospitalized ADHF (all *p* \< 0.05). Our patients in the higher BNP group (BNP \>100 pg/ml) had a graver prognosis than their lower (BNP ≤100 pg/ml) counterparts. Kaplan-Meier survival curves by BNP group are presented in Fig. [1](#Fig1){ref-type="fig"}. (The log-rank test: *χ*2 = 6.78; *p*-value = 0.0092). A local regression scatterplot smoothing of BNP levels and in-hospital mortality risk is presented in Fig. [2](#Fig2){ref-type="fig"}---further confirming BNP as a continuous clinical biomarker and a predictor of in-hospital mortality. Kaplan-Meier survival curves by quartiles (Q) of BNP were Q1 \< 260.5 pg/ml, Q2 (260.5--617 pg/ml), Q3 (618--1340 pg/ml), Q4 ≥ 1341 are presented in Fig. [3](#Fig3){ref-type="fig"}. Mortality rates in the BNP quartiles were tested for trend of survival functions: Chi-square = 11.23; *p*-value = 0.0008. Higher BNP quartiles predicted higher in-hospital mortality.Fig. 1Kaplan-Meier survival curves by BNP group. (The log-rank test: *χ*2 = 6.78; *p*-value = 0.0092)Fig. 2Scatterplot Smoother of admission BNP levels and in-hospital mortalityFig. 3Kaplan-Meier survival curves for BNP quartiles. Test for trend of survival functions: Chi-square = 11.14; *P* = 0.0008

Discussion {#Sec7}
==========

Our cohort study revealed several findings: abnormally high BNP levels, advanced age, pulmonary basilar rales, worse NYHA FC, and a wider QRS duration were independently associated with in-hospital mortality among hospitalized ADHF patients. Admission BNP levels were independently associated with in-hospital mortality. Krim et al. \[[@CR20]\] reported that in a large cohort in North America with 92,072 participants from 264 hospitals, BNP levels at admission in Asian patients averaged 1066 pg/ml; for blacks 866 pg/ml; for whites 776 pg/ml; and for Hispanics 737 pg/ml. BNP levels at admission were 1028 pg/ml in our study, which was comparable to previous studies. Previous data have proposed that BNP levels may vary with genetic factors and that the higher BNP levels observed in Asian populations may be related to higher rates of renal insufficiency \[[@CR20]\]. Indeed, Taiwan has the highest incidence and prevalence rates of end stage renal disease and a high prevalence of CKD \[[@CR23]\], making renal insufficiency a likely cause of the comparatively high average BNP levels in our cohort.

From the large observational database ADHERE (Acute Decompensated Heart Failure National Registry)---a registry contained data on patients hospitalized with acute decompensated HF from 191 hospitals across United States of America---Fonarow et al. \[[@CR22]\] reported that BNP levels at admission independently predicted mortality in ADHF patients hospitalized with reduced and preserved systolic function. To the best of our knowledge, data regarding the clinical presentation and in-hospital prognostic information using prior BNP in an admitted HF cohort remained largely unknown in large Asian populations. Our analysis of a relatively large group of HF hospitalizations confirmed that admission BNP levels can be a reliable and accountable predictor of the risk of in-hospital mortality among hospitalized ADHF. Previously, many other publications reported that BNP contributed independently to the risk prediction of in-hospital mortality. Our analysis shows that admission levels of BNP give prognostic information about patients hospitalized for ADHF. Moreover, it is the first to report in an Asian population. BNP has been globally used to assist clinical decision-making and to critically appraise patients with HF. However, interpretation of BNP measurements also depends on many factors including obesity, CKD, the status of congestion or decongestion, specific treatments, and race/ethnicity among hospitalized ADHF patients \[[@CR12]\]. Similar to prior findings, our work showed that several key clinical co-variates, including worse NYHA FC, presence of rales, wider QRS duration, as well as abnormally high BNP (set at 100 pg/ml) remained as independent prognosticators of in-hospital mortality.

Careful clinical evaluation/reasoning and interpretation of laboratory results in the correct context will always add to laboratory tests alone in patients with complex syndrome of HF. Clinical decision-making involves many factors, including understanding scientific evidence, experience, and the patient's profile. Even if levels of BNP are easily available, yield quick results, and are widely used, they still do not contribute explicit guidance regarding specific HF therapies. Rapid and early patient identification may aid faster progressive therapies that improve a patient's symptoms and enable an estimate of the combined end point of death and failure to achieve a favorable health status \[[@CR24]\]. Our analyses in this observational cohort suggest rales and worse NYHA FC (two congestive signs on physical assessment) were independently associated with in-hospital mortality. Worse functional class has been the most common sign and symptom of heart failure causing patients to seek medical treatment at emergency departments. Early dyspnea relief had been demonstrated to be associated in reduced mortality Dyspnea is an important marker of congestion and a target for treatment. However, there is no validated method of measuring dyspnea in HF patients \[[@CR25]\]. A post-hoc analysis of the AF-CHF (Atrial Fibrillation and Chronic Heart Failure) found that rales was associated with mortality among other congestive signs including peripheral edema, jugular venous distension, and a third sound \[[@CR2]\]. Our study and the AF-CHF Trial continue to show that congestive signs on physical assessment have important prognostic value in HF patients. A retrospective analysis of the CIBIS-II (Cardiac Insufficiency Bisoprolol Study -- II) in 2647 patients with NYHA functional class III to IV symptoms, found that congestive signs of jugular venous distension and peripheral edema were associated with HF in-hospital mortality \[[@CR26]\]. Importantly, rale as a congestive sign on physical assessment was not evaluated \[[@CR2]\]. Further, wide QRS duration had also recently been proved to be a key prognosticator in HF survival and hospitalization \[[@CR27]\]. In line with these prior reports, our study demonstrated that admission levels of BNP, advanced age, worse NYHA FC, wider QRS duration and pulmonary rales were the strongest risk factors for mortality among unplanned hospitalized with ADHF. These analyses suggest that conventional physical assessments in this modern era continue to provide important prognostic value over the more routine clinical parameters of electrocardiography and echocardiography, especially LVEF \[[@CR2]\].

There were a total of 7 % admitted HF subjects who presented with BNP levels \< 100 pg/ml in our current study. Fonarow et al. reported a 3.3 % prevalence of HF subjects with BNP levels \<100 pg/ml from ADHERE (Acute Decompensated Heart Failure National Registry) from 48,629 hospitalizations \[[@CR22]\]. A previous study reported that BNP levels provided the accurate diagnosis of 81.1 % (sensitivity of 90 % and specificity of 74 %) at a cutoff of \>100 pg/ml among congestive heart failure patients presenting at the emergency department \[[@CR21]\]. In our study and a report from ADHERE \[[@CR22]\], patients in the higher BNP quartiles had a higher trend for mortality. Thus admission levels of BNP allow the acquisition of expedited prognostic information regarding in-hospital mortality for hospitalized ADHF patients. Based on our findings, rapid and early recognition of several specific risk factors may benefit a subgroup of patients for whom aggressive optimization of drug or device therapies could improve their outcomes and further provide possible beneficial interventions to improve their in-hospital survival during admission.

Limitations {#Sec8}
-----------

The results of this observational study should be interpreted in the context of several limitations. This is a single center study with retrospective manner and may not represent the general population. Although consecutiveness of enrollment was rigidly recommended, a hospitalized patient census was not checked or available. Therefore, we cannot prove the consecutiveness of patient enrollment. The accuracy and completeness of collected dataset depends on the original documenters. Patients were mainly recruited from the cardiology and pulmonary departments, and thus might not represent the general population. We did not report oral medications at admission. The dataset of home regimen medications was not complete or unavailable.

Conclusion {#Sec9}
==========

Admission BNP levels remained a prognostic value for determining in-hospital mortality among patients with unplanned hospitalization with ADHF in our Asian population. The prognostic value of BNP in such a patient population was also shown to be independent of other clinical or lab data, including echocardiography. Routine clinical implementation of biomarkers for any admitted HF patient has therefore been proposed to better understand the pathophysiological mechanisms and to offer not only a more accurate prediction of the specific patient subgroup at higher risk for unfavorable in-hospital events but also facilitate the introduction of effective therapy, if needed, in a timely fashion.

Key messages {#Sec10}
============

1\. Admission BNP levels provided prognostic value for determining in-hospital mortality among patients with unplanned hospitalization with ADHF in our Asian population.

2\. Congestive signs of pulmonary rales and dyspnea on the physical assessment continue to provide prognostic value.

ADHF

:   Acute decompensated heart failure

BNP

:   B-type natriuretic peptide

CAD

:   Coronary artery disease

CHF

:   Chronic heart failure

CKD

:   Chronic kidney disease

DBP

:   Diastolic blood pressure

GFR

:   Glomerular filtration rate

GPT

:   Glutamate pyruvate transaminase

HbA1c

:   Glycated hemoglobin

LVEF

:   Left ventricular ejection fraction
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:   New York Heart Association functional class
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:   Paroxysmal nocturnal dyspnea
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:   Systolic blood pressure
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